Surf Therapeutics Company Profile

Background

Overview

Surf Therapeutics is a clinical-stage company specializing in non-invasive ultrasound neuromodulation technologies aimed at treating chronic inflammatory disorders. The company's mission is to transform the management of these conditions by leveraging the body's inherent capacity to heal itself through precise, non-invasive ultrasound stimulation. Their vision is to provide accessible, drug-free therapeutic solutions that restore immune balance safely and naturally, enabling patients to manage chronic inflammation from the comfort of their homes.

Industry Significance

In the realm of chronic inflammatory diseases, traditional treatments often involve long-term medication regimens with potential side effects. Surf Therapeutics' innovative approach offers a promising alternative by targeting the body's natural anti-inflammatory pathways, potentially reducing reliance on pharmaceuticals and improving patient quality of life.

Key Strategic Focus

Core Objectives

Surf Therapeutics aims to develop and commercialize a non-invasive ultrasound neuromodulation platform that activates the cholinergic anti-inflammatory pathway, a neural mechanism that modulates immune responses. By stimulating this pathway, the company seeks to provide therapeutic benefits for individuals suffering from chronic inflammatory conditions.

Areas of Specialization

The company's primary focus is on chronic inflammatory disorders, including rheumatoid arthritis, psoriasis, psoriatic arthritis, and multiple sclerosis. Their technology is designed to modulate immune-related pathways without the need for drugs, surgery, or implanted devices.

Key Technologies Utilized

Surf Therapeutics employs a patented broad beam ultrasound platform that delivers gentle acoustic energy into the body to safely activate nerves. This activation leads to the release of natural neurotransmitters, signaling the immune system to shift from uncontrolled inflammation to balance. The technology is intended for at-home use, offering a non-invasive and patient-friendly treatment option.

Primary Markets Targeted

The company's technology targets markets in chronic inflammatory diseases, focusing on providing non-invasive treatment options for patients seeking alternatives to traditional drug therapies.

Financials and Funding

Funding History

Surf Therapeutics has secured funding through various channels, including participation in incubator and accelerator programs. Specific details regarding total funds raised and individual funding rounds are not publicly disclosed.

Recent Funding Rounds

The company has been involved in funding activities, including participation in accelerator programs, though specific details about recent funding rounds are not publicly available.

Notable Investors

Surf Therapeutics has attracted investment from organizations such as MassChallenge U.S., Jumpspace Ventures, Texas Medical Center Venture Fund, General Inception, and Riceberg Ventures.

Utilization of Capital

The capital raised is primarily allocated towards advancing the development of their ultrasound neuromodulation platform, conducting clinical studies, and expanding their research and development efforts to bring their technology to market.

Pipeline Development

Key Pipeline Candidates

Surf Therapeutics is focusing on developing its ultrasound neuromodulation platform for the treatment of chronic inflammatory disorders, with an initial emphasis on rheumatoid arthritis.

Stages of Clinical Trials

The company has initiated an Early Feasibility Study (EFS) to evaluate its investigational ultrasound device in individuals with rheumatoid arthritis. The study is designed to assess the safety and efficacy of the device in activating the cholinergic anti-inflammatory pathway to modulate immune responses. The EFS is expected to enroll up to 40 patients in two stages: an initial open-label pilot followed by a randomized, double-blinded, sham-controlled trial.

Target Conditions

The primary target condition for the current pipeline is rheumatoid arthritis, with potential expansion to other chronic inflammatory diseases such as psoriasis, psoriatic arthritis, and multiple sclerosis.

Anticipated Milestones

Insights from the EFS are expected to inform Surf Therapeutics' future clinical development plans, including preparation for pivotal studies and potential commercialization.

Technological Platform and Innovation

Proprietary Technologies

Surf Therapeutics' proprietary technology is centered around a broad beam ultrasound platform that delivers gentle acoustic energy to activate nerves, leading to the modulation of immune responses through the cholinergic anti-inflammatory pathway. This non-invasive approach aims to provide therapeutic benefits without the need for drugs, surgery, or implanted devices.

Significant Scientific Methods

The company employs ultrasound neuromodulation techniques to engage the body's natural anti-inflammatory pathways. By activating specific neural circuits, Surf Therapeutics aims to restore immune balance and reduce chronic inflammation.

Leadership Team

Key Executives

• Nishant Doctor, MS: Co-founder and Chief Executive Officer.

• Alex Sackeim, MD: Co-founder and Chief Medical Officer.

• Matthew Parker, PhD: Co-founder and Chief Technology Officer.

• Sruthi Suriya, MS: Co-founder and Chief Operating Officer.

• Hrishikesh Kulkarni, PhD: Co-founder and Chief Scientific Officer.

• Paul Amador, MS: Co-founder and Chief Commercial Officer.

• Ingrid Caton, PhD: Co-founder and Chief Regulatory Officer.

Professional Backgrounds and Contributions

• Nishant Doctor, MS: With a background in biomedical engineering, Nishant has experience in medical device development and commercialization. He has been instrumental in leading Surf Therapeutics' strategic direction and growth.

• Alex Sackeim, MD: A physician with expertise in immunology and inflammatory diseases, Alex has contributed to the clinical development and medical strategy of the company's pipeline.

• Matthew Parker, PhD: An expert in biomedical engineering, Matthew has led the technological development of the ultrasound neuromodulation platform.

• Sruthi Suriya, MS: With a background in operations management, Sruthi has overseen the company's operational strategies and execution.

• Hrishikesh Kulkarni, PhD: Specializing in neuroscience, Hrishikesh has guided the scientific research and development efforts of the company.

• Paul Amador, MS: With expertise in business development, Paul has been key in establishing partnerships and commercial strategies.

• Ingrid Caton, PhD: A regulatory affairs specialist, Ingrid has ensured compliance and facilitated the regulatory pathways for the company's products.

Leadership Changes

As of January 2026, Surf Therapeutics announced the addition of two independent board members:

• Jason Witherington, Ph.D.: Brings extensive experience in translational medicine and clinical development across immunology and inflammatory diseases. Previously held leadership roles at Johnson & Johnson, GSK, and Galvani Bioelectronics.

• Shri Raghunathan, Ph.D.: Founder & CEO of Noctrix Health, with significant experience in building and scaling companies, particularly in at-home neuromodulation delivery, regulatory affairs, and reimbursement strategy.

Competitor Profile

Market Insights and Dynamics

The market for non-invasive treatments for chronic inflammatory diseases is growing, driven by the demand for alternative therapies that reduce reliance on pharmaceuticals and improve patient quality of life. Advancements in neuromodulation technologies and increased patient awareness are contributing to this growth.

Competitor Analysis

Surf Therapeutics operates in a competitive landscape that includes both pharmaceutical companies and medical device manufacturers focusing on innovative treatments for chronic inflammatory conditions. Key competitors may include companies developing biologic therapies, other neuromodulation technologies, and non-invasive treatment devices. Specific competitor profiles are not detailed in the available information.

Strategic Collaborations and Partnerships

Surf Therapeutics has established collaborations with leading multinational pharmaceutical companies to evaluate the application of their ultrasound neuromodulation technology in various therapeutic areas. These partnerships aim to integrate Surf Therapeutics' platform into existing product pipelines, enhancing the delivery and efficacy of treatments for chronic inflammatory diseases.

Operational Insights

In comparison to major competitors, Surf Therapeutics differentiates itself through its non-invasive, at-home ultrasound neuromodulation platform, offering a patient-friendly alternative to traditional drug therapies. The company's focus on leveraging the body's natural anti-inflammatory pathways positions it uniquely in the market, potentially providing a competitive edge in terms of patient acceptance and treatment adherence.

Strategic Opportunities and Future Directions

Surf Therapeutics is well-positioned to capitalize on the growing demand for non-invasive treatments for chronic inflammatory diseases. The company's strategic roadmap includes expanding its clinical pipeline, advancing regulatory approvals, and scaling its technology for broader applications. By leveraging its proprietary ultrasound neuromodulation platform, Surf Therapeutics aims to establish itself as a leader in the non-invasive treatment of chronic inflammation, offering patients accessible and effective therapeutic options.